New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?

Show full item record



Permalink

http://hdl.handle.net/10138/301989

Citation

Olkkonen , V M , Sinisalo , J & Jauhiainen , M 2018 , ' New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk? ' , Atherosclerosis , vol. 272 , pp. 27-32 . https://doi.org/10.1016/j.atherosclerosis.2018.03.019

Title: New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Author: Olkkonen, Vesa M.; Sinisalo, Juha; Jauhiainen, Matti
Contributor: University of Helsinki, Medicum
University of Helsinki, Clinicum
Date: 2018-05
Language: eng
Number of pages: 6
Belongs to series: Atherosclerosis
ISSN: 0021-9150
URI: http://hdl.handle.net/10138/301989
Abstract: Remarkably good results have been achieved in the treatment of atherosclerotic cardiovascular diseases (CVD) by using statin, ezetimibe, antihypertensive, antithrombotic, and PCSK9 inhibitor therapies and their proper combinations. However, despite this success, the remaining CVD risk is still high. To target this residual risk and to treat patients who are statin-intolerant or have an exceptionally high CVD risk for instance due to familial hypercholesterolemia (FH), new therapies are intensively sought. One pathway of drug development is targeting the circulating triglyceride-rich lipoproteins (TRL) and their lipolytic remnants, which, according to the current view, confer a major CVD risk. Angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) are at present the central molecular targets for therapies designed to reduce TRL, and there are new drugs emerging that suppress their expression or inhibit the function of these two key proteins. The medications targeting these components are biological, either human monoclonal antibodies or antisense oligonucleotides. In this article, we briefly review the mechanisms of action of ANGPTL3 and apoC-III, the reasons why they have been considered promising targets of novel therapies for CVD, as well as the current status and the most important results of their clinical trials. (C) 2018 Elsevier B.V. All rights reserved.
Subject: 3111 Biomedicine
3121 General medicine, internal medicine and other clinical medicine
ANGPTL3
Antibody therapy
apoC-III
ASO
CVD
TRL
CORONARY EVENTS
ANGIOPOIETIN-LIKE PROTEINS
OF-FUNCTION MUTATIONS
LOW-DENSITY LIPOPROTEINS
METABOLISM
ENDOTHELIAL-CELLS
B GENE
APOLIPOPROTEIN-C-III
FAMILIAL COMBINED HYPOLIPIDEMIA
PLASMA TRIGLYCERIDES
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0021915018301333_main.pdf 605.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record